Amicus Therapeutics, Inc. (FOLD) News
Filter FOLD News Items
FOLD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FOLD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest FOLD News From Around the Web
Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025More on Amicus Therapeutics |
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 People Treated with an Amicus Therapy Today2 PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary |
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20?We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. Driven […] |
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Ther |
HALO or FOLD: Which Is the Better Value Stock Right Now?HALO vs. FOLD: Which Stock Is the Better Value Option? |
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh |
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
HALO vs. FOLD: Which Stock Is the Better Value Option?HALO vs. FOLD: Which Stock Is the Better Value Option? |
Exploring High Growth Tech Stocks In The United States December 2024The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. |